lobbying_activities: 2143775

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2143775	c6f0a95a-9e81-45c2-a457-5c7085445712	Q2	KOUNTOUPES DENHAM CARR & REID, LLC	320918	ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)	2018	second_quarter	PHA	Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of the Vice President of the United States,SENATE,White House Office	60000		0	0	2018-07-13T12:39:35.513000-04:00